| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1998PNAS...95.6919C |
| P356 | DOI | 10.1073/PNAS.95.12.6919 |
| P932 | PMC publication ID | 22686 |
| P698 | PubMed publication ID | 9618514 |
| P5875 | ResearchGate publication ID | 13665012 |
| P50 | author | Lloyd J. Old | Q1866929 |
| P2093 | author name string | Chen YT | |
| Jäger E | |||
| Knuth A | |||
| Stockert E | |||
| Tsang S | |||
| Güre AO | |||
| P2860 | cites work | A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma | Q24307739 |
| A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma | Q24319940 | ||
| Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies | Q24563990 | ||
| Human neoplasms elicit multiple specific immune responses in the autologous host | Q24564371 | ||
| A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening | Q24564781 | ||
| Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration | Q24605561 | ||
| Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes | Q24680097 | ||
| Structure, chromosomal localization, and expression of 12 genes of the MAGE family | Q28238754 | ||
| Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein | Q28240208 | ||
| Identification of a new MAGE gene with tumor-specific expression by representational difference analysis | Q28263448 | ||
| Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3 | Q28264498 | ||
| The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40 | Q28292213 | ||
| Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma | Q28301765 | ||
| Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor | Q28304420 | ||
| Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes | Q32142930 | ||
| SSX: a multigene family with several members transcribed in normal testis and human cancer | Q34447254 | ||
| The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas | Q36362111 | ||
| A survey of the humoral immune response of cancer patients to a panel of human tumor antigens | Q36400634 | ||
| Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy | Q36752428 | ||
| AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization | Q37333876 | ||
| BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes | Q41371291 | ||
| Serological identification of human tumor antigens | Q41642426 | ||
| New paths in human cancer serology | Q41821668 | ||
| Presence on a human melanoma of multiple antigens recognized by autologous CTL. | Q54342793 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 6919-6923 | |
| P577 | publication date | 1998-06-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library | |
| P478 | volume | 95 |
| Q53452776 | A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. |
| Q33851750 | A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature. |
| Q34087776 | A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation |
| Q24676730 | A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma |
| Q37515426 | A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. |
| Q35565945 | A novel zinc finger gene, ZNF465, is inappropriately expressed in acute myeloid leukaemia cells |
| Q42398133 | A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. |
| Q64264461 | Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients |
| Q37952804 | Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy? |
| Q35170387 | Applications of protein microarrays for biomarker discovery |
| Q38127467 | Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome |
| Q30872302 | Autoantibody to DNA binding protein B as a novel serologic marker in systemic sclerosis |
| Q33908182 | Autoantigen discovery with a synthetic human peptidome |
| Q34276512 | Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". |
| Q24531276 | BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma |
| Q35819901 | Biological functions of melanoma-associated antigens |
| Q34154427 | CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients |
| Q33892059 | CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis |
| Q74455929 | CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues |
| Q33242531 | Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer |
| Q49728427 | Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma |
| Q39762419 | Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells |
| Q38435410 | Cancer-testis antigens and immunotherapy in the light of cancer complexity |
| Q35846167 | Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy. |
| Q29616129 | Cancer/testis antigens, gametogenesis and cancer |
| Q28215652 | Cancer/testis antigens: an expanding family of targets for cancer immunotherapy |
| Q34568997 | Cancer/testis antigens: structural and immunobiological properties |
| Q24793404 | Challenges to the development of antigen-specific breast cancer vaccines |
| Q28214444 | Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis |
| Q34147841 | Characterization of sperm protein 17 in human somatic and neoplastic tissue |
| Q36960733 | Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective |
| Q36490771 | Combinatorial cancer immunotherapy |
| Q31013050 | Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens |
| Q30831587 | Construction of human liver cancer vascular endothelium cDNA expression library and screening of the endothelium-associated antigen genes |
| Q28277691 | DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T cells and CD8 T cells |
| Q39652593 | DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma |
| Q31938591 | De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma |
| Q36480998 | Dendritic cell immunotherapy for breast cancer |
| Q34353251 | Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival |
| Q39160149 | EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors |
| Q35005930 | Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens |
| Q34015590 | Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer |
| Q48629050 | Expression of MAGE--A restricted to testis and ovary or to various cancers in dogs. |
| Q33954883 | Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients |
| Q86489861 | Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas |
| Q44781020 | Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis |
| Q34111764 | Expression of cancer-testis (CT) antigens in placenta |
| Q80375978 | Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray |
| Q33892426 | Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. |
| Q58454722 | Expression of cancer/testis (CT) antigens in lung cancer |
| Q31036179 | Expression of cancer/testis antigens in cutaneous T cell lymphomas |
| Q30706370 | Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas |
| Q36178619 | Expression, purification and serological analysis of hepatocellular carcinoma associated antigen HCA587 in insect cells |
| Q34093600 | Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients |
| Q90053381 | Functional expression and impact of testis-specific gene antigen 10 in breast cancer: a combined in vitro and in silico analysis |
| Q37363928 | Genomic and proteomic biomarkers for cancer: a multitude of opportunities. |
| Q24670205 | Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor |
| Q30371297 | H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination. |
| Q36367841 | Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes |
| Q33494714 | Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma |
| Q31045922 | Identification of cancer/testis genes by database mining and mRNA expression analysis |
| Q33841222 | Identification of cancer/testis-antigen genes by massively parallel signature sequencing |
| Q28217586 | Identification of metallopanstimulin-1 as a member of a tumor associated antigen in patients with breast cancer |
| Q24648957 | Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer |
| Q34721861 | Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen |
| Q45238421 | Identification of tumor antigens in malignant mesothelioma |
| Q28188712 | Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues |
| Q35798186 | Immunohistochemistry in melanocytic proliferative lesions |
| Q24554211 | Immunomic analysis of human sarcoma |
| Q38465242 | Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters |
| Q36708792 | Immunotherapy in prostate cancer: emerging strategies against a formidable foe. |
| Q34383950 | Immunotherapy of melanoma |
| Q38682131 | Immunotherapy of melanoma: efficacy and mode of action |
| Q37851050 | Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes |
| Q43830991 | L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma |
| Q77711553 | MAGE-C1 (CT7) gene expression in multiple myeloma: relationship to sperm protein 17 |
| Q54282269 | MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. |
| Q37003608 | Management of breast cancer by vaccine: fact or fiction |
| Q36669988 | Molecular markers of prostate cancer |
| Q35693584 | Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. |
| Q27345217 | Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies |
| Q33855568 | Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers |
| Q33200820 | Multiple variants and a differential splicing pattern of kinectin in human hepatocellular carcinoma |
| Q35995828 | NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery |
| Q34388367 | NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses |
| Q24649090 | NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens |
| Q43081527 | NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma |
| Q53306166 | New hypotheses for large-scale epigenome alterations in somatic cancer cells: a role for male germ-cell-specific regulators. |
| Q37855302 | New technologies in cancer. Protein microarrays for biomarker discovery |
| Q36832141 | Novel antibodies as anticancer agents |
| Q38544350 | Oncogenic cancer/testis antigens: prime candidates for immunotherapy. |
| Q30844391 | Optimised SEREX technique for the identification of leukaemia-associated antigens |
| Q34606735 | PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients |
| Q36613717 | Pattern of cancer/testis antigen expression in lung cancer patients |
| Q30657549 | Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries |
| Q34475795 | Prognostic and diagnostic value of spontaneous tumor-related antibodies |
| Q54649233 | Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. |
| Q33432732 | Proteome serological determination of tumor-associated antigens in melanoma |
| Q33519571 | Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma |
| Q35789880 | Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification |
| Q30695952 | RBP1L1, a retinoblastoma-binding protein-related gene encoding an antigenic epitope abundantly expressed in human carcinomas and normal testis |
| Q34674715 | Retracted: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells |
| Q38202841 | Seminal plasma as a diagnostic fluid for male reproductive system disorders |
| Q30969714 | Serological analysis of BALB/C methylcholanthrene sarcoma Meth A by SEREX: identification of a cancer/testis antigen |
| Q55866684 | Serological detection of cutaneous T-cell lymphoma-associated antigens |
| Q24544114 | Serological detection of cutaneous T-cell lymphoma-associated antigens |
| Q24681820 | Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer |
| Q30785776 | Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients |
| Q37622471 | Serum autoantibodies as biomarkers for early cancer detection |
| Q43616374 | Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer |
| Q51806652 | Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas. |
| Q38564461 | T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma |
| Q36158708 | Targeted therapy for epithelial ovarian cancer |
| Q34081748 | Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines |
| Q28216604 | The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma |
| Q90728910 | The ectopic expression of meiCT genes promotes meiomitosis and may facilitate carcinogenesis |
| Q28216652 | The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis |
| Q34381251 | The journey from autologous typing to SEREX, NY-ESO-1, and cancer/testis antigens |
| Q28218763 | The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer |
| Q35005955 | The use of HLA class I tetramers to design a vaccination strategy for melanoma patients |
| Q36694952 | Transduction of dendritic cells with recombinant adenovirus encoding HCA661 activates autologous cytotoxic T lymphocytes to target hepatoma cells |
| Q38636573 | Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. |
| Q34399765 | Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy |
| Q38787035 | Unmasking targets of antitumor immunity via high-throughput antigen profiling |
| Q27933400 | Yeast homolog of a cancer-testis antigen defines a new transcription complex |
Search more.